Premium
Induction of Immune Response against Metastatic Tumors via Vaccination of Mannan‐BAM, TLR Ligands, and Anti‐CD40 Antibody (MBTA)
Author(s) -
Medina Rogelio,
Wang Herui,
Caisová Veronika,
Cui Jing,
Indig Iris H.,
Uher Ondrej,
Ye Juan,
Nwankwo Anthony,
Sanchez Victoria,
Wu Tianxia,
Nduom Edjah,
Heiss John,
Gilbert Mark R.,
Terabe Masaki,
Ho Winson,
Zenka Jan,
Pacak Karel,
Zhuang Zhengping
Publication year - 2020
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.202000044
Subject(s) - immune system , immunotherapy , tumor microenvironment , cancer research , antibody , antigen , immunology , cancer immunotherapy , cd8 , biology , medicine
Emerging evidence is demonstrating the extent of T‐cell infiltration within the tumor microenvironment has favorable prognostic and therapeutic implications. Hence, immunotherapeutic strategies that augment the T‐cell signature of tumors hold promising therapeutic potential. Recently, immunotherapy based on intratumoral injection of mannan‐BAM, toll‐like receptor ligands and anti‐CD40 antibody (MBTA) demonstrated promising potential to modulate the immune phenotype of injected tumors. The strategy promotes the phagocytosis of tumor cells to facilitate the recognition of tumor antigens and induce a tumor‐specific adaptive immune response. Using a syngeneic colon carcinoma model, MBTA's potential to augment CD8 + T‐cell tumor infiltrate when administered intratumorally or subcutaneously is demonstrated as part of a whole tumor cell vaccine. Both immunotherapeutic strategies prove effective at controlling tumor growth, prolong survival, and induce immunological memory against the parental cell line. Collectively, the investigation demonstrates MBTA's potential to trigger a potent anti‐tumor immune response.